Skip to content

Genmab

US · GMAB #860 by market cap Listed 2019
50.60 -0.75 -1.46%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:56

Price chart

Pre-market 51.67 +0.62%
After-hours 50.02 -1.15%
Overnight 51.25 -0.19%
57.2923.8550.602026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on GMAB?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +59.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 1.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → B

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A
ValuationGrowthProfitMomentumHealthAnalyst
Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 43.2x Better than 12%
Forward P/E 34.8x Better than 14%
Price / Sales 7.8x Better than 14%
P/E vs own 5-yr range 84th pctl Better than 22%
Growth A-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 21.2% Better than 83%
Net income CAGR (3Y) 7.1% Better than 54%
Free cash flow CAGR (3Y) 29.8% Better than 74%
Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 93.6% Better than 98%
Operating margin 33.6% Better than 92%
Net margin 25.9% Better than 86%
Return on equity 17.6% Better than 74%
Return on invested capital 10.9% Better than 72%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 51.3% Better than 100%
6-month return 88.3% Better than 99%
12-month return (ex latest month) 31.4% Better than 70%
Distance below 52-week high 15.6% Better than 70%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.0x Better than 56%
Debt to assets 42.2% Better than 24%
Interest coverage 20.7x Better than 83%
Free cash flow / net income 117.4% Better than 50%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 88.9% Better than 71%
Upside to average target 27.9% Better than 46%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -1.50%
1M +29.51%
3M +51.45%
6M +85.96%
YTD +64.29%
1Y +68.44%
3Y +55.88%
5Y +22.02%

Key statistics

Price & volume

Prev close
51.35
Open
51.57
Day range
50.24 - 51.72
Avg price
50.88
Volume
2.90M
Turnover
147.50M
Amplitude
2.88%
52-week range
23.62 - 59.97

Valuation

P/E
32.92
P/E (TTM)
43.25
P/B
4.93
EPS
1.54
Net profit
947.70M
Net assets
6.33B

Share structure

Market cap
31.20B
Float cap
29.01B
Shares out
616.59M
Float shares
573.24M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-07-18
52-week range 74% of range
23.62 59.97

15.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+1.30M net over the window

Short interest

Shares short
9.66M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Genmab (GMAB)?

Genmab last traded at 50.60. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Genmab's market cap?

About 31.20B.

What is the P/E ratio of Genmab?

The trailing twelve-month P/E is 43.25, above its own 5-year average of 29.46 — toward the top of its historical range (81.43% percentile). See the Valuation tab for the full history.

Does Genmab pay a dividend?

Genmab does not currently pay a regular dividend.

Is Genmab a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 64.57, which implies 27.6% upside from the current price. This is not investment advice.

What is Genmab's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Genmab a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:56:12 · For reference only, not investment advice and not tailored to your situation.

Genmab discussion 0 comments

Add a comment